Company profile for Prilenia therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Prilenia is a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is a world-renowned scientist in Huntington Disease research. He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS....
Prilenia is a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is a world-renowned scientist in Huntington Disease research. He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS. The company has recently raised $62.5M in a Series A financing round to launch the planned HD and ALS late-stage clinical trials.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Gooimeer 2/35, 1411 DC NAARDEN, Netherlands
Telephone
Telephone
+972-77-5558482
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251211232354/en/Prilenia-and-Ferrer-Announce-FDA-Clearance-to-Start-the-PREVAiLS-Pivotal-Phase-3-Study-with-Pridopidine-in-ALS

BUSINESSWIRE
11 Dec 2025

https://www.businesswire.com/news/home/20251010035801/en/Prilenia-and-Ferrer-to-Share-New-Data-and-Analyses-of-Pridopidines-Impact-on-Huntingtons-Disease-at-the-Huntington-Study-Group-HSG-Congress

BUSINESSWIRE
10 Oct 2025

https://www.businesswire.com/news/home/20251006420172/en/Pridopidine-Pivotal-Phase-3-ALS-Study-Unveiled-at-NEALS-2025-Annual-Meeting

BUSINESSWIRE
06 Oct 2025

https://www.ferrer.com/en/Nature-Medicine-Publishes-Phase-3-Data-on-Pridopidine-in-Early-Stage-Huntingtons-Disease-Highlighting-Impact-on-Clinical-Progression

PRESS RELEASE
05 Sep 2025

https://www.businesswire.com/news/home/20250725635763/en/Prilenia-and-Ferrer-Provide-Update-on-European-Regulatory-Process-for-Pridopidine-in-Huntingtons-Disease

BUSINESSWIRE
25 Jul 2025

https://www.ferrer.com/en/Prilenia-and-Ferrer-Provide-Update-on-European-Regulatory-Process-for-Pridopidine-in-Huntington%E2%80%99s-Disease

PRESS RELEASE
25 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty